Study Title: A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
For more information about the trial above please contact the study team:Medical University of South CarolinaPrincipal Investigator, Alexander, Mariam, at alexanma@musc.edu.Study Coordinator, Morgan, Shelby, at morshelb@musc.edu.Trial opened at the following institutions: Medical University of South Carolina